Collegium Pharmaceutical Just Updated Its 2020 Guidance. Is It a Buy?
This biotech stock is promising strong revenue figures and a net profit for 2020.
Collegium Pharmaceutical
COLL
COLL
$23.41
-$0.51
-2.1%
BATS BZX Real Time Price as of January 17, 2020, 4:00 p.m. EST
View Interactive COLL Charts
COLLEGIUM PHARMACEUTICAL INC COM USD0.001
News & Analysis: Collegium Pharmaceutical
About to Buy Penny Stocks? Look at These 3 Companies First
Buying proven businesses is better than scouring the pink sheets looking for a viable investment.
Why Collegium Pharmaceutical Stock Is Crushing It Today
Investors are excited about the drugmaker's big formulary wins for its abuse-deterrent opioid drug.
Collegium Pharmaceutical Inc (COLL) Q3 2019 Earnings Call Transcript
COLL earnings call for the period ending September 30, 2019.
Collegium Pharmaceutical, Inc. (COLL) Q2 2019 Earnings Call Transcript
COLL earnings call for the period ending June 30, 2019.
Collegium Pharmaceutical, Inc. (COLL) Q1 2019 Earnings Call Transcript
COLL earnings call for the period ending March 31, 2019.
2 Big Biotech Stock Upgrades: Can They Reach These Targets?
Investment-bank analysts think these drugmakers are worth a lot more than the stock market does at the moment.
Collegium Pharmaceutical Inc (COLL) Q4 2018 Earnings Conference Call Transcript
COLL earnings call for the period ending December 31, 2018.
Here's Why Collegium Pharmaceutical Rose as Much as 23.5% Today
The company is acquiring a new drug with over $200 million in annual sales, but it won't be cheap.
Why Collegium Pharmaceutical Shares Are Tumbling 12.9% Today
The FDA is working on ways to encourage the development of abuse-deterrent opioid pain relievers, and that's potentially bad news for this tiny biotech.
